M

Mirador Therapeutics

Develops precision therapies for immune-mediated diseases

Senior Director - Clinical Pharmacology

Clinical Research OperationsConfirmed live in the last 24 hours
Full-timeSan Diego, CA, USA

About the Job

Requirements

  • PhD, PharmD, or equivalent experience in clinical pharmacology, pharmacology, pharmaceutical sciences, or a related discipline; candidates are assessed on demonstrated program delivery rather than degree.
  • 10 or more years of biotech or pharmaceutical industry experience in early clinical development, with a track record of delivering Phase 1 studies as the sponsor’s accountable lead.
  • Experience serving as Study Director or equivalent sponsor lead on first-in-human studies, including dose-escalation studies in healthy volunteers and/or patients.
  • Experience authoring and amending clinical protocols and keeping an IND current, including IND amendments, annual reports or DSURs, and responses to information requests.
  • Working knowledge of PK/PD and model-informed drug development sufficient to design sampling schemes, interpret noncompartmental and exposure–response outputs, and critically review pharmacometric deliverables.
  • Familiarity with bioanalysis, biomarkers, biostatistics, data management, toxicology, and regulatory disciplines in drug development.
  • Thorough understanding of ICH Good Clinical Practice and regulatory requirements for Phase 1 conduct, IND maintenance, and safety reporting, including sound judgment on protocol deviations, documentation, and inspection readiness.
  • Strong protocol and regulatory writing skills, clear written and oral communication, and attention to detail.
  • Ability to lead cross-functional study teams and external partners to outcomes without direct authority.
  • Project and financial management discipline, including building credible budgets and timelines and managing to them.
  • Scientific acumen to integrate safety, PK, PD, and biomarker data into dose-escalation and go-forward recommendations.
  • Ability to work on several studies and programs simultaneously and prioritize effectively.
  • Ability to adapt to change and take on new therapeutic areas.
  • Commitment to collaborative leadership, teamwork, delegation, and fostering a professional culture based on trust and mutual respect.

Responsibilities

  • Serve as Study Director for several concurrent Phase 1 studies, including first-in-human single- and multiple-ascending-dose studies and clinical pharmacology studies such as relative bioavailability, formulation or device bridging, drug interaction, and special population studies; ensure scientific integrity, quality, and timelines from protocol concept through clinical study report.
  • Author Phase 1 protocols and amendments with Medical Writing, lead cross-functional review and approval, co-develop study-design and dose-selection rationale with the Head of function, and translate it into protocol text, dose-escalation and stopping rules, and PK/PD and biomarker sampling schemes.
  • Act as the sponsor’s primary day-to-day interface with Phase 1 units, investigators, and CROs; lead study team meetings, track start-up, enrollment, dosing, and data flow, anticipate risks, and resolve issues to keep studies on plan.
  • Partner with the study medical monitor to run safety review committee and dose-escalation meetings and ensure integrated safety, PK, and PD data are available, reviewed, and documented for escalation decisions.
  • Select, contract, and manage study vendors with Clinical Operations, including CROs, Phase 1 units, bioanalytical, biomarker, and central laboratories, and data systems; scope work orders and change orders and hold vendors accountable to quality, timelines, and budgets.
  • Own data quality from first subject dosed through database lock; review safety, PK, PD, and biomarker data in near real time, drive data cleaning and query resolution with Data Management and the CRO, and oversee bioanalytical sample logistics and PK data reconciliation.
  • Lead study analysis and reporting; provide input to statistical analysis plans, oversee noncompartmental PK analysis and PK/PD summaries, interpret safety, PK, PD, and biomarker results, author or direct clinical study reports and clinical pharmacology sections, and present results to program teams and governance.
  • Support operational regulatory deliverables for INDs with Regulatory Affairs, including authoring and reviewing clinical and clinical pharmacology content of IND modules and amendments, Investigator’s Brochure updates, annual reports and DSURs, and responses to health authority information requests.
  • Prepare study-level content for regulatory briefing documents and meeting packages and support the Head of function in health authority interactions.
  • Support clinical pharmacology needs of later-phase programs by contributing to clinical pharmacology development plans, integrated PK/PD and exposure–response summaries, and rationale for the recommended Phase 2 dose and regimen.
  • Support in-licensing due diligence by evaluating external assets’ clinical pharmacology and Phase 1 data packages, identifying gaps and risks, and contributing to clinical pharmacology assessments.
  • Apply PK/PD and model-informed drug development approaches as needed to inform study design, dose selection, and data interpretation, and oversee pharmacometric deliverables from vendors and consultants in alignment with the function’s PK/PD and MIDD strategy.
  • Represent Clinical Pharmacology and Early Clinical Development on program teams for Phase 1 assets; partner with R&D to integrate biomarker and translational endpoints into Phase 1 designs and ensure sample collection, assay readiness, and data flow support the proof-of-concept plan.
  • Contribute to internal process improvement, including SOPs, templates, and study-level quality documentation, and maintain inspection readiness for sponsor-owned Trial Master File content.
  • Contribute to hiring, onboarding, and mentoring as the team grows.
  • Travel up to 10%.

Desired Qualifications

  • Hands-on modeling experience, such as Phoenix WinNonlin, NONMEM, or R.
  • Experience in immunology or inflammation and across biologics and small-molecule modalities.
  • Experience contributing to later-phase clinical pharmacology deliverables, including clinical pharmacology plans and Phase 2 dose selection, or to due diligence assessments.

About the Company

Mirador Therapeutics

Develops precision therapies for immune-mediated diseases

Mirador Therapeutics develops precision therapies for immune-mediated inflammatory and fibrotic diseases. The company uses advanced biology, multi-modal data, and analytics to create treatments that target specific immune pathways involved in these conditions. Its products work by modulating immune responses in a patient-specific way, with data guiding which patients are most likely to benefit from a given therapy. Mirador differentiates itself through its focus on precision medicine and data-driven design, led by former executives from Prometheus Biosciences, and by pursuing partnerships as well as direct commercialization. The goal is to improve patient outcomes by delivering targeted therapies that address the underlying immune mechanisms of inflammation and fibrosis.

Company size
51-200
Company stage
Series B
Total funding
$650M
Headquarters
San Diego, CA
Founded
2024

Recently Posted Jobs

Explore more opportunities at Mirador Therapeutics

See more jobs